Clinical trial NCT06926933: Efficacy and Safety of Leuprolide Acetate 45 mg in Subjects With Central Precocious Puberty
Official title: An Open Label, Single-group, Multicenter Study on the Efficacy and Safety of Leuprolide Acetate 45 mg for Injectable Suspension-controlled Release in Subjects With Central (Gonadotropin-dependent) Precocious Puberty
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE4
Conditions: CPP
Lead sponsor: HanAll BioPharma Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2025-04-15
Enrollment: 50
Sex: ALL
Minimum age (years): 4
Maximum age (years): 9
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is a multicenter, open-label, single-group, and phase 4 study to evaluate the efficacy and safety of 45 mg of leuprolide acetate in CPP.

Screening tests are performed after the subject agrees in writing to participate in the clinical trial, and subjects who meet the inclusion criteria and do not fall under the exclusion criteria are enrolled in the study. The target patients in this study are pediatric patients who have been diagnosed with CPP but have not yet received GnRH agonist treatment, and all subjects perform GnRH stimulation tests to confirm their CPP diagnosis.


Eligibility criteria: Inclusion Criteria:

1. Pubertal-type LH response following an abbreviated GnRH stimulation test before treatment initiation \> 5 IU/L
2. A subject manifested with central precocious puberty according to the following criteria Age : Boy (4 years of age or older \~ under 9 years of age) Girl (4 years of age or older \~ under 8 years of age) Tanner Stage : Level 2 or higher
3. Based on baseline visit (Day 0), those under the age of 10 for boys and those under the age of 9 for girls
4. Confirmed diagnosis of CPP within 12 months of Baseline Visit (Day 0) but have not received prior GnRH agonist treatment for CPP
5. Children with a body weight of more than 20 kg at screening
6. Children have a bone age that is ≥1 year older than their chronological age at screening
7. A signed written consent form by a legal representative who has been informed about this study

Exclusion Criteria:

1. Gonadotropin-independent (peripheral) precocious puberty: extra pituitary secretion of gonadotropins or gonadotropin-independent gonadal or adrenal sex steroid secretion
2. Prior or current GnRH treatment for CPP
3. Non-progressing isolated premature thelarche
4. Presence of an unstable intracranial tumor or an intracranial tumor requiring neurosurgery or cerebral irradiation. Subjects with hamartomas not requiring surgery are eligible.
5. Prior (within 12 weeks of Screening) use of medications

   * Hormonal agonists (Estrogen, Progesterone, FSH, LH, Testosterone etc.)
   * Hormonal antagonists (Anti-Estrogen agents, Anti-Androgen agents)
   * Steroid use (except for mild topical steroids, oral steroids are allowed within 30 days)
   * Herbal Medicines
6. Prior or current therapy with growth hormone
7. Major medical or psychiatric illness that could interfere with study visits
8. Diagnosis of short stature (i.e. 2 standard deviations (SD) below the mean height for age or 3rd percentile for age)
9. Pregnant or likely pregnant women (Positive urine pregnancy test), nursing women
10. Known hypersensitivity to GnRH or related compounds
11. Any other medical condition or serious intercurrent illness that, in the opinion of the investigator, may make it undesirable for the subject to participate in the study
12. Any other condition(s) which could significantly interfere with Protocol compliance
13. Treatment with an investigational product within 5 half-lives of that product in prior clinical studies before the baseline visit (Day 0)
14. Known history of seizures, epilepsy, and/or central nervous system disorders that may be associated with seizures or convulsions
15. Prior (within 6 months of Baseline (Day 0)) or current use of medications that, per investigator opinion, have been associated with seizures or convulsions

Primary outcomes:
measure: The percentage (%) of subjects with serum LH concentrations < 4 IU/L following an GnRH stimulation test
timeFrame: at week 24
Secondary outcomes:
measure: The percentage (%) of subjects with suppressed serum LH concentrations (< 4 IU/L) 30-minutes post GnRH stimulation test
timeFrame: at week 12, 48, 72, 96
measure: The percentage (%) of subjects with suppressed serum FSH (< 2.5 mIU/mL), estradiol (< 20 pg/mL, for girl) or testosterone (< 30 ng/dL, for boy)
timeFrame: at week 12, 24, 48, 72, 96
measure: The percentage of subject of Tanner stage (including menstruation)
timeFrame: at week 12, 24, 48, 72, 96
measure: Height velocity (growth rate)
timeFrame: at week 12, 24, 48, 72, 96
measure: The ratio of bone age and chronological age
timeFrame: at week 12, 24, 48, 72, 96
Other outcomes:
Locations:
city: Ansan
country: Korea, Republic of
facility: Korea University Ansan Hospital
city: Jeonju
country: Korea, Republic of
facility: Jeonbuk National University Hospital
city: Kwangju
country: Korea, Republic of
facility: Chosun University Hospital
city: Seongnam
country: Korea, Republic of
facility: Seoul National University Bundang Hospital
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center
city: Seoul
country: Korea, Republic of
facility: Gangnam Severance Hospital
city: Seoul
country: Korea, Republic of
facility: Kangdong Sacred Heart Hospital
city: Seoul
country: Korea, Republic of
facility: Kyung Hee University Hospital At Gangdong
city: Suwon
country: Korea, Republic of
facility: Ajou University Medical Center
Study officials:
affiliation: Hanall Biopharma
name: Eunhee Lee
role: STUDY_DIRECTOR
References: